Tobias Nordström is a clinically active urologist, focusing on the detection and treatment of malignancies in the prostate and kidney, as well as treating general urological conditions. He started practicing urology 2007 and have achieved degrees in General Surgery and Urology at Danderyds Hospital. He was awarded Fellow of the European Board of Urology (FEBU) in 2015.
Tobias Nordström defended the thesis "Predicting Prostate Cancer- on the use of biomarkers in Prostate Cancer Diagnostics" in January 2015 after which he undertook international postdoctoral studies at University of California, San Francisco.
He combines clinical surgical practice at Danderyds Hospital with independent research at Karolinska Institutet. Centrepieces of his work includes leading guidelines development and implementing improvements in clinical care such as targeted prostate biopsies and imaging.
2015- Postdoc (Dpt Medical Epidemiology and Biostatistics, KI)
2015- Clinical Urologist (Danderyds Hospital)
2015 Fellow of the European Board of Urology (FEBU)
2015 Postdoc (University of California, San Francisco)
2015 Ph.D. (Dpt Clinical Sciences at Danderyds Hospital, KI)
2013 General Surgeon (Danderyds Hospital)
2007 M.D. (KI)
The over-arching aim of Tobias Nordströms research is to improve detection and treatment of prostate cancer. Current work emanates from different perspectives, resulting in several different projects.
An improved diagnostic chain for prostate cancer
The hypothesis is that combining improved blood-based testing and imaging techniques will improve detection of prostate cancer. Tobias Nordström is principal investigator for the STHLM3MR-projects, aiming to investigate the value of Magnetic Resonance Imaging (MRI) in prostate cancer detection. The STHLM3MR Main study is a large randomized study, exploring a combination of using the STHLM3 test and targeted biopsies using MRI/Fusion tehnique.
Traditional tools for prostate cancer detection
Several tools are already availiable to aid decisions in prostate cancer diagnostics, but evidence are often scarce. Using contemporary, high-quality data, dr Nordström systematically explore the value of traditionally used markers of prostate cancer risk such as prostate volume, voiding symtoms, repeated blood-testing et cetera.
Current diagnostics of prostate cancer
Using the populationbased cohort STHLM0, dr Nordström work with describing how detection of prostate cancer is currently being performed. For example, he described current patterns of PSA-testing, use of prostate biopsies and frequency of biopsy-related complications.
Academic honours, awards and prizes
2017 Astellas Cutting Edge Award
2016 European Association of Urology (EAU) Annual Meeting - Best poster award
2014 StratCan International Postdoc award
2011 StratCan Ph.D. award
2011 Research Resident
Nobels väg 12A